Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00256880 · ClinicalTrials.gov registry record · Phase 2
Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
A Phase 2 study of Carcinoma, Renal Cell, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT00256880 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 100 participants, below the 280-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (64% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT00256880, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
Conditions Studied
Interventions
- DRUG GW786034
Study Locations (8)
Victoria
- GSK Investigational Site - East Melbourne
- GSK Investigational Site - Melbourne
- GSK Investigational Site - Melbourne
Arkansas
- GSK Investigational Site - Little Rock
Massachusetts
- GSK Investigational Site - Boston
North Carolina
- GSK Investigational Site - Durham
Pennsylvania
- GSK Investigational Site - Philadelphia
Washington
- GSK Investigational Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00256880
The ClinicalTrials.gov registry entry for NCT00256880 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (64% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which GW786034 is the first listed.
NCT00256880 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Victoria, Arkansas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00256880 about?
NCT00256880 is a clinical study titled "Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma". The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Bl...
What is the current status of trial NCT00256880?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2005-01. Estimated completion is 2005-12.
What conditions does trial NCT00256880 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00256880?
The interventions under investigation include: GW786034 (DRUG).
Who is sponsoring clinical trial NCT00256880?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00256880 being conducted?
This trial has 8 study locations across Arkansas, Massachusetts, North Carolina, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Dendritic Cell Vaccine in Kidney Cancer
RECRUITING · Phase 2
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.